Navigation Links
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Date:3/17/2008

eutical Development, and Chief Medical Officer. "Our approach mirrors our strategy for Genasense in melanoma in which a smaller Phase 3 trial, expected to complete accrual later this year, seeks to confirm efficacy by focusing on patients who derived maximum benefit in a large randomized trial. In parallel with collection and analysis of existing data in CLL, Genta has developed a new clinical trial, and the Company will file its draft protocol seeking formal Scientific Advice at the May meeting of the European Medicines Agency (EMEA). Genta greatly appreciates the professional and collaborative communications with FDA during this process, and we look forward to working closely with FDA in addressing their recommended options for securing the confirmatory data."

Proposed Confirmatory Trial of Genasense in CLL

The proposed protocol, based on results obtained during the previous trial, is a randomized controlled trial at first or second relapse in patients who are "non-refractory". All patients will receive fludarabine plus cyclophosphamide (Flu/Cy) - an accepted standard of care - and they will be randomly assigned to receive Genasense or no additional therapy. The trial will seek to confirm that the addition of Genasense increases complete responses (CR) in patients who receive Flu/Cy chemotherapy.

In the preceding Phase 3 trial, 241 patients with relapsed or refractory CLL were randomly assigned to receive Flu/Cy with or without Genasense. This study achieved its primary endpoint - an increase in the proportion of patients who achieved CR (17% vs. 7%; P=0.025). By definition, CR represents the complete elimination of all clinical signs of leukemia, combined with the elimination of leukemia-related symptoms. The duration of CR was also significantly longer for patients treated with Genasense (i.e., median not yet reached but exceeding 36 months in the Genasense group compared with 22 months for the Flu/Cy-only group).

In patients predefin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
2. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
3. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
11. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... SAN DIEGO , Sept. 18, 2014 /PRNewswire/ ... today announced that the U.S. Food and Drug ... patient enrollment and dosing of PEGPH20 in SWOG,s ... is designed to evaluate Halozyme,s investigational drug PEGPH20 ... FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients with metastatic pancreatic ...
(Date:9/18/2014)... After 6 months of careful research with the ... new programme for the next Cool Chain & Temperature Controlled ... Chain series, has just been released! You can ... lines between supply chain, logistics, QA and purchasing continue to ... and yet specific, focused and yet accessible, inclusive and targeted ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... oncology electronic medical record (EMR) – the ... certification under the HITECH Act – has propelled Elekta ... / hematology EMR vendors in the annual Black Book ... a "comprehensive ambulatory EMR vendor" were: electronic health records ...
... Therapeutics, Inc. (OTCBB: ECTE), a company developing its ... transdermal continuous glucose monitoring system and its Prelude™ ... that Patrick T. Mooney, M.D., CEO, President and ... present at the Jefferies 2011 Global Healthcare Conference. ...
Cached Medicine Technology:Elekta's MOSAIQ Far Ahead of Contenders in Black Book Rankings User Survey of EMR Vendors 2Elekta's MOSAIQ Far Ahead of Contenders in Black Book Rankings User Survey of EMR Vendors 3
(Date:9/18/2014)... Active Aging Week is a week-long observance ... members of society and promotes the benefits of leading ... a boutique retirement community located at 1200 Overlook Drive, ... of Cyber-Seniors - a humorous and heartwarming documentary. , ... this great film,” says Thomas Cloutier, Executive Director for ...
(Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
(Date:9/18/2014)... Reinberg HealthDay Reporter , THURSDAY, Sept. ... outbreak in West Africa is starting to spread faster than ever, ... cases of the deadly viral infection were reported in just one ... than 5,300, with roughly half of those reported in the past ... deaths now tops 2,600. WHO has estimated that as many ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 Companies ... and refine carbon dioxide, selling it to downstream industries ... markets for carbon dioxide are food and beverage manufacturers. ... such as fruits, vegetables or pizzas. The gas is ... manufacturers use the compound to carbonate soft drinks, beer ...
(Date:9/18/2014)... exercise is good for you. But new research from ... an added benefit for cancer patients undergoing chemotherapy. , ... found that combining exercise with chemotherapy shrunk tumors more ... professor in the School of Nursing and director of ... the senior author on the study, which appears in ...
Breaking Medicine News(10 mins):Health News:In Support of Active Aging Week, a Lake Oswego Retirement Community Will Get a Sneak Peek at an Inter-Generational Documentary – Cyber-Seniors 2Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2
... medical center,s dramatic growth and steady ... over nearly four decades, GLEN BURNIE, Md., Sept. 18 ... those as president and CEO,James R. Walker has announced his ... night at the BWMC Board of Directors meeting. (Photo: ...
... Expanded leave,benefits for military families is a ... to balance the needs of employees and employers, ... the world,s largest,association of human resource professionals., ... for members of the,National Guard, Reservists and their ...
... Quality Forum (NQF) and The Joint Commission today announced the,2007 ... Quality,Awards. Honorees were selected in all four award categories., ... ACHIEVEMENT (2 RECIPIENTS), -- Flaura Koplin Winston, M.D., Ph.D. ... Prevention at The Children,s Hospital of Philadelphia and the ...
... is quiet almost too quiet in movies, it is ... good guys. This holds true for the genes that protect against ... Ohio, have learned. They identified a panel of 15 genes that ... becomes quiet almost too quiet -- it could mean they ...
... In an 18-year-study on attention-deficit hyperactivity disorder (ADHD), ... stimulants is associated with improved long-term academic success ... are the first population-based data to show stimulant ... A related Mayo Clinic study reveals that compared ...
... study finds , , TUESDAY, Sept. 18 (HealthDay News) -- ... by looking at Web sites can leave would-be patients ... study finds. , In looking over six hospital-comparison Web ... inappropriate or incomplete standards to measure a center,s quality, ...
Cached Medicine News:Health News:BWMC President and CEO Announces Retirement 2Health News:BWMC President and CEO Announces Retirement 3Health News:SHRM Testimony Urges Congress to Fix FMLA 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 3Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 4Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 5Health News:Test for lung cancer looks for discomforting quiet among protective genes 2Health News:Test for lung cancer looks for discomforting quiet among protective genes 3Health News:Mayo Clinic study indicates medication for ADHD may help student outcomes 2Health News:Mayo Clinic study indicates medication for ADHD may help student outcomes 3Health News:Hospital Quality Info on Web Can Be Misleading 2Health News:Hospital Quality Info on Web Can Be Misleading 3
... offered as either EDTA K2 or ... calcium ions and therefore blocks the ... in an EDTA anticoagulated blood sample ... hours. EDTA tubes are for the ...
... Tissue transglutaminase (tTg) is a ... of proteins. Tissue transglutaminase is also ... by the endomysial antibody immunofluorescence (EMA) ... 29060). Anti-tTg IgA and,IgG serologic tests ...
... the training it needs with the NetLearning ... Human Capital Management System in one. Whether ... JCAHO and HIPAA, understanding compliance reporting for ... skills through continuing education courses, the NetLearning ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: